The Competition Board finalized the preliminary inquiry conducted to determine whether Medsantek Laboratuar Malzemeleri San. ve Tic. Ltd. Şti. and Genomed Sağlık Hizmetleri A.Ş,which are authorized distributors of ThermoScientific’s DNA sequence analysis devices, abused their dominant position they hold in the market for the said devices’ sales and maintenance in the market for kits used in those devices and violated the Act No. 4054.

After discussing the information and documents acquired and observations made during the preliminary inquiry in its meeting of 24.04.2018, the Board concluded that the findings were significant and sufficient, and took the decision no 18-12/214-M to initiate an investigation about the following undertakings in order to determine whether the undertakings in question violated the Act no 4054:

• Medsantek Laboratuar Malzemeleri San. ve Tic. Ltd. Şti.
• Genomed Sağlık Hizmetleri A.Ş.

*Investigation decisions taken by the Competition Board are announced to the public following the notification of the decision to the undertakings or associations of undertakings under investigation. Those announcements, which are made within the framework of informing the public about the decisions of the Competition Board, cannot be interpreted to mean that the undertakings or associations of undertakings under investigation have violated the Act no 4054, or they are or will be subject to penal sanctions under the Act.